RATIONALE-315: Perioperative tislelizumab in 1L resectable NSCLC

24 Jul 2025

BeOne Medicines

Chapters

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s,
Recent Advances in CLL research and management

Recent Advances in CLL research and management

Dr. Renata Walewska
Recent Advances in CLL research and management

Recent Advances in CLL research and management

Dr. Renata Walewska
Recent Advances in CLL research and management

Recent Advances in CLL research and management

Dr. Renata Walewska
Recent Advances in CLL research and management

Recent Advances in CLL research and management

Dr. Renata Walewska

Speakers

Mariano Provencio

Related content

DISEASE EDUCATION

RATIONALE-312: Long-term follow-up in ES-SCLC

Solid Tumors • BeGenius Spotlight Series
FIND OUT MORE
DISEASE EDUCATION

Efficacy of PD-(L)1 inhibitors for NSCLC in Asian vs. non-Asian populations

Solid Tumors • BeGenius Spotlight Series
FIND OUT MORE
DISEASE EDUCATION

Managing toxicity with BTK inhibitors in Waldenström’s macroglobulinemia

Hematology • BeGenius Spotlight Series
FIND OUT MORE

BeGenius Webinars

Explore educational content in blood cancers, delivered by global experts. Browse previous webinar recordings...

FIND OUT MORE

BeGenius Summits

Access on-demand discussions led by international experts and learn more about relevant topics in hematology.

FIND OUT MORE

BeGenius Patient Cases

Enhance your understanding of patient care with our interactive case studies on the diagnosis and treatment of...

FIND OUT MORE

BeGenius Spotlight Series

Stay up-to-date with recent developments and best-practice in your field with these bite-sized updates from...

FIND OUT MORE

BeGenius Steering Committee

Meet the team of international experts behind all BeGenius content and activities.

FIND OUT MORE

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed